Prevalence of HPV-DNA and anti-HPV antibodies in women from Girardot, Colombia.
OBJECTIVE
To assess the frequency of HPV-DNA detection, human papillomavirus (HPV) seropositivity, presence of cervical lesions, and its relationship with certain socio-demographic factors in women from Girardot, Colombia from 2006 to 2007.


METHODS
Nine hundred fifty-three women attending their regular Pap smear control voluntarily provided cervical cells and blood samples for HPV-DNA analysis and ELISA detection of anti-L1 peptides and virus-like particles (VLPs) antibodies after answering a questionnaire regarding sexual behaviors, number of births, smoking habits, and socio-demographic background.


RESULTS
Twenty-six of the 953 women being examined (2.73%) presented cervical cell abnormalities. A frequency of 36.62% (95% CI: 33.52%-39.7%) HPV seropositivity was detected with peptide 18301, 35.36% (95% CI: 32.3%-38.4%) with 18283, and 32.95% (95% CI: 29.9%-36%) with 18294, whereas VLPs detected a 43% seropositivity (95% CI: 39.8%-46.2%). Antibody frequency found with all peptides was significantly higher in women having cervical abnormalities (atypical squamous cells of undetermined significance and high-grade squamous intraepithelial lesions) compared with those having normal cytologies. Peptide 18283 reported a significantly higher seropositivity (35.71%) in women >44 years old, whereas peptides 18301 and 18294 evidenced a significantly lower seropositivity in those who had never given birth. HR-HPV-DNA was detected in 157 (20.50%) of 766 cervical samples amplifying positively for the beta-globin housekeeping gene.


CONCLUSIONS
Peptides 18283, 18294, and 18301 were more specific and more sensitive than VLPs for detecting women with HR-HPV-DNA positive cervical lesions. Therefore, they could be useful in the design of a serological test for detecting HR-HPV-infected women having cervical lesions at a risk of progressing to cervical cancer.
Leon
Sandra
S
Fundación Instituto de Inmunología de Colombia, Bogotá, Colombia.
Sánchez
Ricardo
R
Patarroyo
Manuel A
MA
Camargo
Milena
M
Mejia
Adriano
A
Urquiza
Mauricio
M
Patarroyo
Manuel E
ME
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000595:Amino Acid Sequence; D000914:Antibodies, Viral / Q000097:blood*; D036022:Capsid Proteins / Q000276:immunology*; D003105:Colombia / Q000453:epidemiology; D004279:DNA, Viral / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D000939:Epitopes / Q000276:immunology; D005260:Female; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification*; D006801:Humans; D008403:Mass Screening; D008875:Middle Aged; D008969:Molecular Sequence Data; D009856:Oncogene Proteins, Viral / Q000276:immunology*; D030361:Papillomavirus Infections / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology*; D010455:Peptides / Q000276:immunology; D012424:Rural Population; D016036:Seroepidemiologic Studies; D012959:Socioeconomic Factors; D002583:Uterine Cervical Neoplasms / Q000453:epidemiology / Q000821:virology; D014771:Virion / Q000276:immunology; D002578:Uterine Cervical Dysplasia / Q000453:epidemiology / Q000821:virology
D000914:Antibodies, Viral; D036022:Capsid Proteins; D004279:DNA, Viral; D000939:Epitopes; D009856:Oncogene Proteins, Viral; D010455:Peptides; C063317:L1 protein, Human papillomavirus type 16